Welcome to our dedicated page for Oncocyte news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte stock.
Oncocyte Corporation develops molecular diagnostic technologies focused on solid organ transplant monitoring and oncology. Company news centers on its blood-based transplant rejection assays, including GraftAssure research-use-only kits, VitaGraft clinical monitoring tests, and the GraftAssureCore lab-developed test, along with reimbursement updates, clinical publications, and development of regulated kitted products for transplant centers.
Updates also cover quarterly results, pharma services activity from its laboratory operations, strategic relationships such as Bio-Rad, capital actions, investor conference participation, and oncology assays such as DetermaIO and DetermaCNI.
Oncocyte Corporation (NYSE American: OCX) has announced its approval to list on the Nasdaq Global Market, effective March 8, 2021. This transition is expected to enhance visibility and market liquidity, attracting institutional investors and potentially boosting shareholder value. The company is known for its molecular diagnostics aimed at cancer care, with recent product launches like DetermaRx and DetermaIO to improve diagnostic capabilities. CEO Ron Andrews highlighted the listing as a significant milestone for growth.
Oncocyte Corporation (NYSE American: OCX) announced its participation in a Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 4:30 PM EST. This event will be accessible via a live webcast and will later have a replay available on the company's investor website. Oncocyte focuses on molecular diagnostics to enhance cancer care through proprietary tests such as DetermaRx and DetermaIO, aimed at improving patient outcomes and driving company revenue growth.
Oncocyte Corporation (NYSE American: OCX) has successfully closed its public offering of 8,947,000 shares of common stock at $4.50 per share, raising approximately $40.3 million. With this offering, the company’s total outstanding shares are now 87,608,810. The funds will be used to commercialize the DetermaRx™ diagnostic test, complete development of DetermaIO™, and for future tests in the pipeline, including a merger with Chronix Biomedical. This transaction was managed by Piper Sandler as the Sole Book-Runner.
Oncocyte Corporation (NYSE American: OCX) has priced an underwritten public offering of 7,780,000 shares at $4.50 each, expected to generate approximately $35 million in gross proceeds. Set to close around February 9, 2021, the offering includes a 30-day option for underwriters to purchase an additional 1,167,000 shares. Funds will be utilized for the commercialization of DetermaRx™, development of DetermaIO™, future tests, and potential acquisitions, including a merger with Chronix Biomedical. The offering is conducted under a shelf registration statement effective June 18, 2019.
Oncocyte Corporation (NYSE American: OCX) has announced an underwritten public offering of its common stock. The offering will include an option for underwriters to purchase an additional 15% of shares. Proceeds from this offering are intended to support the commercialization of the DetermaRx™ diagnostic test, complete development of DetermaIO™, and fund future tests, including the CNI Monitor test through a merger with Chronix Biomedical. The offering is subject to market conditions and the actual terms may vary.
Oncocyte Corporation (NYSE American: OCX) has announced the presentation of a scientific poster on its DetermaRx™ test at the IASLC 2020 World Conference on Lung Cancer. The test, which identifies early-stage lung cancer patients who may benefit from adjuvant chemotherapy, has seen broad adoption across 80 hospitals. Analysis from 250 cases shows it reclassifies 19% of patients without high-risk features as high/intermediate risk, indicating its clinical utility. DetermaRx demonstrated improved survival rates of 92% in treated patients, underscoring its significance in lung cancer management.
Oncocyte Corporation (OCX) announced a registered offering of approximately $25 million in common shares priced at $3.424 each. This offering is led by existing investor Pura Vida Investments and Broadwood Partners, increasing Pura Vida's stake to around 16%. The funds will bolster Oncocyte's balance sheet, facilitating the launch of DetermaIO and DetermaTX while supporting ongoing cancer diagnostics development. After this offering, Oncocyte expects to have over $37 million in cash. The offering is anticipated to close during the week of January 26, 2021.
Oncocyte Corporation (NYSE American: OCX) announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 15, 2021, at 10:45 AM EST. The conference aims to provide a platform for the company to present its advancements in molecular diagnostics, particularly in cancer care. Investors can register for the conference through the provided link and access a replay of the presentation on Oncocyte's website post-event. The company's innovative products, such as DetermaRx™ for lung cancer recurrence and DetermaIO™ for immunotherapy response, are integral to its mission of enhancing cancer treatment outcomes.
Oncocyte Corporation (NYSE American: OCX) announced its participation in the 13th Annual LD Micro Main Event Conference on December 15, 2020. The company will present from 12:40 PM to 1:00 PM EST. Investors can register for the event online. Following the presentation, a replay will be available on Oncocyte's investor website. Oncocyte focuses on providing actionable diagnostics across the cancer care continuum, with products like DetermaRx™, which identifies high-risk lung cancer patients, and DetermaIO™, assessing tumor responses to immunotherapies.
Oncocyte has signed an exclusive licensing agreement with Burning Rock Biotech in China for its DetermaRx test, which identifies high-risk early-stage lung cancer patients. The agreement includes payments of up to $6M in the first year, and ongoing royalties per test. The technology transfer is expected in Q1 2021, with installation by Q3. This marks Oncocyte's fifth global licensing agreement, enhancing its presence in a major market for early-stage lung cancer, with significant potential for revenue growth and improved patient outcomes.